LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Aandelen Lijst・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Gesloten

SectorGezondheidszorg

2.88 -1.03

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.82

Max

2.95

Belangrijke statistieken
By Trading Economics
Inkomsten	4.1M -5.7M
Werknemers	34
EBITDA	3.1M -6.8M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+587.29% upside

Dividenden
By Dow Jones
Volgende Winsten	19 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-88M 300M
Vorige openingsprijs	3.91
Vorige sluitingsprijs	2.88

Nieuwssentiment

By Acuity

50%

157 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

8.275 / 9.312 Steun & Weerstand

Anavex Life Sciences Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 mei 2026, 23:10 UTC

Populaire aandelen

Stocks to Watch: Agilysys, XP

18 mei 2026, 18:44 UTC

Belangrijke Marktbewegers

Claritev Shares Recover After Comments About DOJ

18 mei 2026, 23:55 UTC

Winsten

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mei 2026, 23:47 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

18 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mei 2026, 23:37 UTC

Marktinformatie

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mei 2026, 22:31 UTC

Acquisities, Fusies, Overnames

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mei 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mei 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mei 2026, 22:25 UTC

Acquisities, Fusies, Overnames

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mei 2026, 22:24 UTC

Acquisities, Fusies, Overnames

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

18 mei 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

18 mei 2026, 20:25 UTC

Winsten

Correct: XP 1Q Total Client Assets BRL1.53T

18 mei 2026, 20:23 UTC

Winsten

XP 1Q Total Client Assets BRL1.53B

18 mei 2026, 20:19 UTC

Winsten

XP 1Q Adj EPS BRL2.49 >XP

18 mei 2026, 20:19 UTC

Winsten

XP 1Q Rev BRL4.73B >XP

18 mei 2026, 19:10 UTC

Marktinformatie

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mei 2026, 19:00 UTC

Winsten

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mei 2026, 18:52 UTC

Marktinformatie

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mei 2026, 18:17 UTC

Marktinformatie

Acquisities, Fusies, Overnames

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mei 2026, 17:22 UTC

Marktinformatie

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mei 2026, 16:57 UTC

Acquisities, Fusies, Overnames

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mei 2026, 16:57 UTC

Marktinformatie

Global Energy Roundup: Market Talk

18 mei 2026, 16:57 UTC

Marktinformatie

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mei 2026, 16:54 UTC

Acquisities, Fusies, Overnames

Vinci Doesn't Set Out Financial Details of Deal

18 mei 2026, 16:50 UTC

Acquisities, Fusies, Overnames

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mei 2026, 16:49 UTC

Acquisities, Fusies, Overnames

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mei 2026, 16:49 UTC

Acquisities, Fusies, Overnames

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mei 2026, 16:48 UTC

Acquisities, Fusies, Overnames

Vinci Buys Canada's Modern Group of Companies

Peer Vergelijking

Prijswijziging

Anavex Life Sciences Corp Prognose

Koersdoel

By TipRanks

587.29% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 20 USD 587.29%

Hoogste 20 USD

Laagste 20 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Anavex Life Sciences Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Anavex Life Sciences Corp - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

8.275 / 9.312Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

157 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.